Poor
Not Aligned
Patient Risk:
Moderate
Summary
The response includes multiple musculoskeletal symptom descriptions and clinical expectations (mobility/range-of-motion effects, timing during continued use, reversibility framing) that are not supported by the provided FDA label text for Skeletal Muscle (5.1) and Muscle Pain (17.1). Several statements appear to broaden or reinterpret symptoms beyond what the label explicitly says, leading to poor on-label alignment.
Category Scores
Accurate Statements
Lipitor (atorvastatin) can affect muscles in some patients.
Supported: 5.1 (myopathy/myopathy-related symptoms and rhabdomyolysis risk).
Statins are known to cause muscle-related side effects in a subset of people.
Supported: 5.1 (myopathy with statins; risk increased with certain factors).
Statin-related muscle side effects are most commonly muscle aches or weakness.
Supported: 5.1 (myopathy defined as muscle aches or muscle weakness).
Patients should seek prompt medical advice if they develop marked or rapidly worsening muscle pain or weakness while taking Lipitor.
Supported in concept: 5.1 advises patients to report promptly unexplained muscle pain, tenderness, or weakness (particularly if accompanied by malaise or fever) and to discontinue if myopathy is diagnosed or suspected.
Clinicians may review other medicines for interactions if muscle symptoms occur.
Supported: 5.1 (concomitant use of certain drugs increases risk; monitoring and weighing benefits/risks).
The risk of muscle side effects that could limit flexibility is higher with certain drug interactions that raise statin exposure or strain muscles.
Supported: 5.1 (higher risk with higher doses with cyclosporine/strong CYP3A4 inhibitors) and 7 (risk increased with fibric acid derivatives, niacin, cyclosporine, strong CYP3A4 inhibitors).
Unsupported Statements
Muscle pain or weakness can reduce freedom of movement and can make joints feel stiffer and reduce range of motion.
Not supported in provided label text (5.1/17.1). Label discusses muscle aches/weakness and CPK elevation, not joint stiffness or range-of-motion outcomes.
Reduced flexibility in range of motion can occur due to muscle discomfort, muscle tightness, or weakness caused by Lipitor.
Not supported in provided label text (5.1/17.1).
Symptoms that may suggest Lipitor is affecting mobility or range of motion include new muscle pain, soreness, or cramping.
Partially supported at best for muscle pain/tenderness/weakness, but 'soreness or cramping' and framing as 'mobility/range of motion' are not supported by the provided label wording.
Symptoms that may suggest Lipitor is affecting mobility or range of motion include muscle weakness (e.g., trouble rising from a chair or climbing stairs).
Muscle weakness is label-consistent, but the specific functional examples ('rising from a chair,' 'climbing stairs') are not supported by provided label text.
Symptoms that may suggest Lipitor is affecting mobility or range of motion include stiffness that makes stretching or daily movement feel harder.
Not supported in provided label text (5.1/17.1).
Statin-related muscle symptoms usually develop after starting treatment or after dose increases.
Timing details are not stated in the provided label text.
Statin-related muscle symptoms can also appear after a period of continued use in some cases.
Not supported in provided label text.
The risk of muscle side effects that could limit flexibility is higher with higher statin doses.
The label supports increased risk with higher doses in the presence of certain interacting drugs, but does not broadly support 'higher statin doses' as a general factor without that context.
The risk of muscle side effects that could limit flexibility is higher in older age.
Not supported in provided label text (5.1/7/17.1).
The risk of muscle side effects that could limit flexibility is higher with kidney or liver problems.
Label supports renal impairment as a risk factor for rhabdomyolysis and requires closer monitoring, but liver-problem-related risk for muscle side effects is not supported by the provided text.
The risk of muscle side effects that could limit flexibility is higher with strenuous physical activity, dehydration, or other stresses on the body.
The provided label mentions conditions such as severe acute infection, hypotension, major surgery, trauma, severe metabolic/endocrine/electrolyte disorders, and uncontrolled seizures as acute serious conditions suggestive of myopathy/risk for renal failure; it does not support 'strenuous physical activity' or 'dehydration' as stated.
Dark or cola-colored urine can be a sign of serious muscle injury associated with statin use.
Not supported in provided label text.
Fever or feeling very unwell can be a sign of serious muscle injury associated with statin use.
The label supports reporting muscle symptoms particularly if accompanied by malaise or fever, but the broader framing about 'serious muscle injury' and 'feeling very unwell' is not explicitly stated.
Clinicians may stop Lipitor temporarily or adjust the dose if muscle symptoms occur.
Label supports discontinuation if markedly elevated CPK occurs or myopathy is diagnosed/suspected, and recommends temporarily withholding or discontinuing in patients with acute serious conditions suggestive of myopathy or having risk factors. 'Adjust the dose' is not explicitly stated in the provided label text.
Clinicians may check labs such as muscle enzymes and other markers if muscle symptoms occur.
Label mentions periodic CPK determinations may be considered in certain interaction situations, but does not explicitly support 'muscle enzymes and other markers' broadly for symptoms.
Clinicians may switch to a different statin or alternative lipid-lowering therapy depending on cause and severity if flexibility/muscle symptoms occur.
Not supported in provided label text.
In many cases where statin-related muscle symptoms are the cause, symptoms can improve after the medication is reduced, held, or changed.
Not supported in provided label text.
Contradictions
Important Omissions
Label-specific guidance: LIPITOR should be temporarily withheld or discontinued in any patient with an acute, serious condition suggestive of myopathy or having a risk factor for renal failure secondary to rhabdomyolysis (examples listed in 5.1).
Importance:
Moderate
Label-specific definition/criteria: myopathy is defined as muscle aches or muscle weakness with CPK >10 times ULN (5.1).
Importance:
Moderate
Caution/thresholds for interacting agents: e.g., do not exceed 10 mg daily with cyclosporine; caution when exceeding 20 mg daily with clarithromycin/itraconazole/HIV protease inhibitors (Table 1).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported symptom characterization (range-of-motion/joint stiffness) and unlabelled clinical expectations (general timing, reversibility, urine/fever framing) could mislead users about what to expect and what actions are label-supported. However, core warning content about muscle pain/tenderness/weakness reporting and interaction risk is partially aligned.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Not Aligned
Primary Issue
Multiple claims expand beyond the provided label text, especially by adding range-of-motion/joint stiffness interpretations, specific functional examples, general timing and reversibility statements, and urine/fever indicators that are not supported by the supplied sections.
Suggested Improvement
Restrict symptom descriptions to label-supported wording (unexplained muscle pain, tenderness, weakness; myopathy definition with CPK >10x ULN). Remove or rephrase unsupported specifics (range-of-motion/joint stiffness, functional examples, urine color, general timing after dose changes/continued use, and broad reversibility). Align management statements with label language: promptly report symptoms; discontinue if myopathy/marked CPK; and temporarily withhold/discontinue when acute serious conditions/risk factors are present; reflect interaction-specific dosing limits where provided.